

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI620602

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BIOPHARMA CREDIT PLC	11/08/2024
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	Immunocore Limited
<b>Street Address:</b>	92 Park Drive, Milton Park
<b>City:</b>	Abingdon, Oxfordshi
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	OX144RY
<b>PROPERTY NUMBERS Total: 13</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	8519100
Patent Number:	9068178
Patent Number:	10130721
Patent Number:	10517960
Patent Number:	10576162
Patent Number:	10420846
Application Number:	13319597
Application Number:	16151144
Application Number:	16305838
Application Number:	17423843
Patent Number:	7329731
Patent Number:	7763718
PCT Number:	US2232261
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2025218721
<b>Email:</b>	ipteam@cogencyglobal.com
<b>Correspondent Name:</b>	Troy Jones
<b>Address Line 1:</b>	1025 Connecticut Ave NW, Suite 712

PATENT

<b>Address Line 2:</b>	Cogency Global Inc.
<b>Address Line 4:</b>	Washington, DISTRICT OF COLUMBIA 20036

<b>NAME OF SUBMITTER:</b>	Andrew Hackett
---------------------------	----------------

<b>SIGNATURE:</b>	Andrew Hackett
-------------------	----------------

<b>DATE SIGNED:</b>	11/11/2024
---------------------	------------

**Total Attachments: 8**

source=Pharmakon\_Immunocore - Termination and Release of Security Interest in Patents (2024)#page1.tiff  
source=Pharmakon\_Immunocore - Termination and Release of Security Interest in Patents (2024)#page2.tiff  
source=Pharmakon\_Immunocore - Termination and Release of Security Interest in Patents (2024)#page3.tiff  
source=Pharmakon\_Immunocore - Termination and Release of Security Interest in Patents (2024)#page4.tiff  
source=Pharmakon\_Immunocore - Termination and Release of Security Interest in Patents (2024)#page5.tiff  
source=Pharmakon\_Immunocore - Termination and Release of Security Interest in Patents (2024)#page6.tiff  
source=Pharmakon\_Immunocore - Termination and Release of Security Interest in Patents (2024)#page7.tiff  
source=Pharmakon\_Immunocore - Termination and Release of Security Interest in Patents (2024)#page8.tiff

## **TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS**

This TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS (this “Termination and Release”) dated as of November 8, 2024 (this “Termination and Release”) is made by BIOPHARMA CREDIT PLC, as collateral agent for the Lenders and the other Secured Parties (in such capacity, the “Collateral Agent”), in favor of IMMUNOCORE LIMITED, a private company with limited liability incorporated under the laws of England and Wales and limited by shares under registration number 06456207 (the “Grantor”).

### **RECITALS:**

WHEREAS, the Grantor is party to that certain Guaranty and Security Agreement, dated as of November 8, 2022 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”; terms used in this Termination and Release and not otherwise defined herein have the meanings set forth in the Guaranty and Security Agreement), by and among the Grantor, the Collateral Agent and the other parties thereto, pursuant to which the Grantor granted a security interest to the Collateral Agent in the Patent Collateral (as defined below), including, but not limited to, those Patents listed on Schedule A hereto;

WHEREAS, the Grantor entered into that certain Patent Security Agreement, dated as of November 8, 2022 (the “Patent Security Agreement”), granting the Collateral Agent security interests in and liens on certain patents described therein (the “Patent Collateral”);

WHEREAS, the Patent Security Agreement was recorded with the United States Patent and Trademark Office (“USPTO”) on November 8, 2022 at Reel/Frame 061899/0866;

WHEREAS, the Grantor has requested that the Collateral Agent enter into this Termination and Release in order to effectuate, evidence and record the release and termination, and reassignment to the Grantor, of any and all right, title and interest the Collateral Agent may have in the Patent Collateral pursuant to the Patent Security Agreement; and

WHEREAS, the Collateral Agent desires to terminate and release its security interest in the Patent Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees:

**SECTION 1. Release of Security Interest.** The Collateral Agent hereby releases, terminates and discharges all liens and security interests the Collateral Agent has in, to and under the Patent Collateral under the Patent Security Agreement.

**SECTION 2. Filing the Release.** The Collateral Agent authorizes and requests that this Termination and Release be filed and recorded at the USPTO at the Grantor’s sole cost and expense.

SECTION 3. Counterparts; Electronic Transmission. This Termination and Release may be executed and delivered by facsimile or other means of electronic transmission and such transmission shall constitute an original for all purposes.

SECTION 4. Governing Law. THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.


*[Signature Page Follows]*

IN WITNESS WHEREOF, the undersigned has executed this Termination and Release by its duly authorized officer as of the date first above written.

BIOPHARMA CREDIT PLC,  
as Collateral Agent

By: Pharmakon Advisors, LP,  
its Investment Manager

By: Pharmakon Management I, LLC,  
its General Partner

By   
Name: Pedro Gonzalez de Cosio  
Title: Managing Member

Schedule A

Patent Collateral

Patent Registrations

Assignee	Territory	Application No.	Effective filing date	Patent No.
<b>T cell receptors</b>				
Immunocore Limited	PCT	PCT/GB2010/001277	1-Jul-2010	expired
Immunocore Limited	AU	2010267758	1-Jul-2010	2010267758
Immunocore Limited	BR	BR112012000107.8	1-Jul-2010	
Immunocore Limited	CA	2766505	1-Jul-2010	2766505
Immunocore Limited	CN	201410257886.8	1-Jul-2010	ZL201410257886.8
Immunocore Limited	EA	201270135	1-Jul-2010	026918
Immunocore Limited	EP	10734524.1	1-Jul-2010	2448963
Immunocore Limited	HK	12110227.0	1-Jul-2010	1169422
Immunocore Limited	JP	2012-518126	1-Jul-2010	5872464
Immunocore Limited	JP	2015-196799	1-Jul-2010	6186412
Immunocore Limited	MX	MX/a/2012/000155	1-Jul-2010	333387
Immunocore Ltd.	US	13/342579	1-Jul-2010	8,519,100
Immunocore Ltd.	US	13/947580	1-Jul-2010	9,068,178
Immunocore Limited	ZA	2011/09522	1-Jul-2010	2011/09522
<b>Bifunctional polypeptides</b>				
Immunocore Limited	PCT	PCT/GB2010/000988	19-May-2010	expired
Immunocore Limited	AU	2010250951	19-May-2010	2010250951
Immunocore Limited	BR	PI1013029.2	19-May-2010	
Immunocore Limited	CA	2762604	19-May-2010	2762604
Immunocore Limited	CA	2968393	19-May-2010	2968393
Immunocore Limited	CN	201080022523.6	19-May-2010	ZL201080022523.6

Immunocore Limited	EA	201101660	19-May-2010	020841
Immunocore Limited	EP	10720803.5	19-May-2010	2432802
Immunocore Limited	EP	16176246.3	19-May-2010	3112376 (Revoked)
Immunocore Limited	EP	16176249.7	19-May-2010	3112377 (Revoked)
Immunocore Limited	JP	2012-511333	19-May-2010	5667171
Immunocore Limited	MX	MX/a/2011/012184	19-May-2010	340168
Immunocore Limited	US	13/319597	19-May-2010	10,130,721
Immunocore Limited	US	16/151144	19-May-2010	
Immunocore Limited	US	16/378481	8-Apr-2019	10,517,960
Immunocore Limited	US	16/378501	8-Apr-2019	10,576,162
Immunocore Limited	US	16/378505	8-Apr-2019	10,420,846
Immunocore Limited	ZA	2011/08460	19-May-2010	2011/08460
<b>Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein</b>				
Immunocore Limited	PCT	PCT/GB2017/051596	2-Jun-2017	expired
Immunocore Limited	AU	2017273147	2-Jun-2017	
Immunocore Limited	BR	BR112018074748-3	2-Jun-2017	
Immunocore Limited	CA	3025894	2-Jun-2017	
Immunocore Limited	CN	2017800485644	2-Jun-2017	
Immunocore Limited	EP	17734131.0	2-Jun-2017	
Immunocore Limited	JP	2018-562926	2-Jun-2017	
Immunocore Limited	MX	MX/a/2018/014863	2-Jun-2017	
Immunocore Limited	RU	2018142197	2-Jun-2017	2766119
Immunocore Limited	RU	2022101491	2-Jun-2017	
Immunocore Limited	US	16/305838	2-Jun-2017	

Immunocore Limited	ZA	2018/08128	2-Jun-2017	2018/08128
Immunocore Limited	HK	19130551.5	2-Jun-2017	
<b>Formulations</b>				
Immunocore Limited	PCT	PCT/EP2020/051002	16-Jan-2020	expired
Immunocore Limited	AU	2020209991	16-Jan-2020	
Immunocore Limited	BR	BR112021014031-0	16-Jan-2020	
Immunocore Limited	CA	3126611	16-Jan-2020	
Immunocore Limited	CN	2020800223681.00	16-Jan-2020	
Immunocore Limited	EP	20701703.9	16-Jan-2020	
Immunocore Limited	HK	62022053519.4.	16-Jan-2020	
Immunocore Limited	IL	284691	16-Jan-2020	
Immunocore Limited	IN	202117032037	16-Jan-2020	
Immunocore Limited	JP	2021-541283	16-Jan-2020	
Immunocore Limited	KR	10-2021-7025022	16-Jan-2020	
Immunocore Limited	MX	MX/a/2021/008578	16-Jan-2020	
Immunocore Limited	NZ	778471	16-Jan-2020	
Immunocore Limited	RU	2021120366	16-Jan-2020	
Immunocore Limited	US	17/423843	16-Jan-2020	
Immunocore Limited	ZA	2021/04876	16-Jan-2020	
<b>Formulations</b>				
Immunocore Limited and AstraZeneca (co-owners)	PCT	PCT/US2022/032261 <sup>1</sup>	3-Jun-2022	
<b>Platform<sup>2</sup></b>				

<sup>1</sup> This patent is jointly-owned with AstraZeneca.

<sup>2</sup> The patents listed under the section labeled “Platform” are jointly-owned with Adaptimmune Limited,



Immunocore Limited and Adaptimmune Limited (co-owners)	PCT	PCT/GB02/03986	30-Aug-2002	
Immunocore Limited and Adaptimmune Limited (co-owners)	AU	2002321581	30-Aug-2002	2002321581
Immunocore Limited and Adaptimmune Limited (co-owners)	CA	2457652	30-Aug-2002	2457652
Immunocore Limited and Adaptimmune Limited (co-owners)	CN	02819279.6	30-Aug-2002	ZL 02819279.6
Immunocore Limited and Adaptimmune Limited (co-owners)	EA	200400384	30-Aug-2002	006601
Immunocore Limited and Adaptimmune Limited (co-owners)	EP	02755287.6	30-Aug-2002	1421115
Immunocore Limited and Adaptimmune Limited (co-owners)	HK	4109015.8	30-Aug-2002	1066018
Immunocore Limited and Adaptimmune Limited (co-owners)	IL	160359	30-Aug-2002	160359
Immunocore Limited and Adaptimmune Limited (co-owners)	IN	00647/CHENP/2004	30-Aug-2002	212621
Immunocore Limited and Adaptimmune Limited (co-owners)	JP	2003-525033	30-Aug-2002	4317940
Immunocore Limited and Adaptimmune	KR	10-2004-7003158	30-Aug-2002	10-0945977

Limited (co-owners)				
Immunocore Limited and Adaptimmune Limited (co-owners)	MX	PA/a/2004/001974	30-Aug-2002	246738
Immunocore Limited and Adaptimmune Limited (co-owners)	NO	2004 1325	30-Aug-2002	331877
Immunocore Limited and Adaptimmune Limited (co-owners)	NZ	531208	30-Aug-2002	531208
Immunocore Limited and Adaptimmune Limited (co-owners)	PL	PL368980	30-Aug-2002	208712
Immunocore Limited and Adaptimmune Limited (co-owners)	SG	200400713.4	30-Aug-2002	200400713-4
Immunocore Limited and Adaptimmune Limited (co-owners)	US	10/486924	30-Aug-2002	7329731
Immunocore Limited and Adaptimmune Limited (co-owners)	US	11/926391	30-Aug-2002	7763718
Immunocore Limited and Adaptimmune Limited (co-owners)	ZA	2004/01197	30-Aug-2002	2004/01197